WAA A.I CyberSecurity Scoring
25/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Waters | Andrew Alliance in 2026.
No incidents recorded for Waters | Andrew Alliance in 2026.
No incidents recorded for Waters | Andrew Alliance in 2026.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Latest updates, reports, and threat intel affecting the global network.
The Gauteng Provincial Government's latest cybersecurity disaster exposes a critical failure of basic infrastructure.
Stellar Cyber, the cybersecurity illumination company behind the industry's leading human-augmented autonomous SOC platform,...
HGC Global Communications is delighted to announce that Daniel Ho, Vice President, Unified Cyber Security and Digital Transformation...
The House Committee on Homeland Security welcomed the passage of two key measures, H.R. 5078, the Protecting Information by Local Leaders...
Ecuador strengthens its cyber defenses with support from US firms, including Resecurity, to counter digital threats and protect national...
Learn how FIDO Alliance's innovations in passkeys and verifiable credentials transform authentication, reducing reliance on passwords for...
Discover Illumio CEO Andrew Rubin's leadership lessons from the Master Move podcast, from building through uncertainty to leading with...
Following the introduction of a bipartisan bill earlier this month by members of the U.S. Homeland Security and Governmental Affairs...
A vulnerability was found in ggml-org llama.cpp bec4772f6. The impacted element is the function deserialize_tensor of the file ggml/src/ggml-rpc/ggml-rpc.cpp of the component ggml-RPC Server. Performing a manipulation of the argument op/op_params results in deserialization. The attack may be initiated remotely. This vulnerability is distinct from CVE-2026-34159 (GHSA-j8rj-fmpv-wcxw, PR #20908), which only added a buffer==nullptr rejection in create_node() and does not validate op or op_params. The reported GitHub issue was closed automatically due to inactivity.
A vulnerability has been found in CTFd up to 3.8.4. The affected element is the function _is_safe_url of the file CTFd/utils/validators/__init__.py. Such manipulation of the argument Next leads to open redirect. The attack can be launched remotely. The exploit has been disclosed to the public and may be used. The name of the patch is 5d8515842fd1ab2c3a9f2dde9ffca907aa334ea9. Upgrading the affected component is recommended.
A vulnerability was identified in code-projects Barangay Resident Profiling Management System 1.0. Affected by this vulnerability is an unknown functionality of the file /boarders.php of the component Boarder Management Module. Such manipulation of the argument ID leads to authorization bypass. The attack can be executed remotely. The exploit is publicly available and might be used.
A vulnerability was determined in code-projects Barangay Resident Profiling Management System 1.0. Affected is an unknown function of the file residents.php of the component Resident Search Functionality. This manipulation of the argument Search causes sql injection. Remote exploitation of the attack is possible. The exploit has been publicly disclosed and may be utilized.
A vulnerability was found in code-projects Barangay Resident Profiling Management System 1.0. This impacts an unknown function of the file /archived_records.php of the component Restore/Delete. The manipulation of the argument resident_id results in authorization bypass. The attack may be launched remotely. The exploit has been made public and could be used.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.